Investors

2017 News

Webcast ImageWebcast
BMO Capital Markets: Prescriptions for Success Healthcare Conference (Live)
12/14/17 at 1:30 p.m. ET
BMO Capital Markets: Prescriptions for Success Healthcare Conference
Thursday, December 14, 2017 1:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/01/17Coherus BioSciences Management to Present at BMO’s Prescriptions for Success Healthcare Conference
REDWOOD CITY, Calif., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be participating in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 1:30 p.m. EST being held in New York, NY. The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coh... 
Printer Friendly Version
11/06/17Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results
REDWOOD CITY, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2017. Corporate Highlights for the Third Quarter 2017 Include: Immunology (anti-TNF) therapeutic franchise: CHS-0214 (etanercept (Enbrel®) biosimilar candidate)    -  Filed petitions for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation o... 
Printer Friendly Version
11/01/17Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be participating in a fireside chat at the Credit Suisse Scottsdale Healthcare Conference on Tuesday, November 7, 2017 at 4:45pm ET being held in Scottsdale, AZ. The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a... 
Printer Friendly Version
10/23/17Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th
REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2017 financial results will be released after market close on Monday, November 6th, 2017.  Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing third quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://in... 
Printer Friendly Version
09/07/17Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
Patent Trial and Appeal Board Denies Institution REDWOOD CITY, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office denied institution of all four of its petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 9,085,619 (“the ‘619 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation. “While we are disappointed by this outcome, we c... 
Printer Friendly Version
09/01/17Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare conferences. Management participation in a fireside chat is scheduled at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:30 a.m. ET taking place in Boston, MA. Management participation in a fireside chat is scheduled at the Baird 2017 Global Healthcare Conference on Thursday, S... 
Printer Friendly Version
08/28/17Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
REDWOOD CITY, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from the first of three ongoing pharmacokinetic bioequivalence (“PK/BE”) studies comparing CHS-1420, a proposed adalimumab (“Humira”) biosimilar candidate versus European marketed Humira. The study met the criteria for clinical PK/BE on all prospectively defined endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last t... 
Printer Friendly Version
08/21/17Coherus Secures Private Placement from Temasek
First tranche of $75 million secured REDWOOD CITY, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced plans to raise up to $150 million in a two tranche private placement, the first tranche of $75 million in aggregate gross proceeds to be completed and funded by August 31, 2017 with 6,556,116 shares of common stock to be issued at an offering price of $11.44 per share. Temasek, an investment company headquartered in Singapore, plans to invest ... 
Printer Friendly Version
08/07/17Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results
REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended June 30, 2017. Corporate Highlights for the Second Quarter 2017 Include: Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) •  Announced completion of initial phases of the Biologic Price Competition and Innovation Act patent exchange with Amgen. •  Announced receip... 
Printer Friendly Version
08/07/17Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522
REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has filed a petition for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation of U.S. Patent 8,163,522 (“ ‘522 patent”). The ‘522 patent, controlled by Amgen, is generally directed to a method for making etanercept, the pharmaceutically active component of ENBREL®. Coherus also announced its intention to file an IPR in the near fu... 
Printer Friendly Version
07/24/17Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2017 financial results will be released after market close on Monday, August 7, 2017.  Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing second quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://inve... 
Printer Friendly Version
06/12/17Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
Management to host a call today at 8:00 a.m. EDT to discuss FDA feedback REDWOOD CITY, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its biologics license application (“BLA”) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, under the 351(k) pathway. The CRL primarily focused on the FDA request for a reanalysis of a subset of ... 
Printer Friendly Version
06/01/17Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program 
REDWOOD CITY, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th NASDAQ OMX Investor Program on Thursday, June 15, 2017 in London, UK at 11:30 am GMT.  The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a leading pure-play, global biosimilar company that dev... 
Printer Friendly Version
05/16/17Coherus BioSciences Prevails in ‘135 IPR Decision
Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135 REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the ‘135 Patent).  The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rh... 
Printer Friendly Version
05/08/17Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended March 31, 2017. Corporate Highlights for the First Quarter 2017 Include: Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (Humira®) biosimilar candidate) Reported positive topline 24-week treatment results for CHS-1420 in patients with psoriasis. Announced filing of four petiti... 
Printer Friendly Version
05/01/17Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
REDWOOD CITY, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. A fireside chat is scheduled at Deutche Bank’s 42nd Annual Health Care Conference on Wednesday, May 3rd at 10:40 a.m. EDT taking place in Boston, MA. A company presentation is scheduled at the Bank of America/Merrill Lynch Healthcare Conference on Thursday, May 18th at 8:40 a.m. PDT taking ... 
Printer Friendly Version
04/25/17Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
REDWOOD CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), announced today that it completed the initial phases of the Biologics Price Competition and Innovation Act (BPCIA) patent exchange procedure with Amgen for Coherus’ Neulasta (pegfilgrastim) biosimilar candidate, CHS-1701.  Of the two patents originally listed by Amgen in the process, the parties have reached agreement on a single patent for potential litigation, U.S. patent 8,273,707 (the ‘707 pat... 
Printer Friendly Version
04/24/17Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017.  At 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing first quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus... 
Printer Friendly Version
03/27/17Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
REDWOOD CITY, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development.  Mr. Wiberg joins Coherus with more than 30 years of experience, including more than 18 years in various business development and corporate finance roles at biopharmaceutical companies, and 13 years in healthcare investment banking and equity research.  In this position, Mr. Wiberg will be responsi... 
Printer Friendly Version
03/13/17Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
REDWOOD CITY, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the fourth quarter and full year 2016. Corporate Highlights for the Fourth Quarter 2016 Include: Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) - Announced that the U.S. FDA has accepted the filing of 351(k) Biologics License Application (BLA) for CHS-1701. The first FDA submissi... 
Printer Friendly Version
03/06/17Coherus Addresses Trade Secret Action Filed by Amgen
REDWOOD CITY, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that Amgen has filed a trade secret action in California state court on March 3, 2017 alleging trade secret misappropriation and other claims against Coherus and other parties.  “Coherus believes that this action is without merit and will defend against it vigorously,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “We categorically reject the theme of Amg... 
Printer Friendly Version
03/02/17Statement by Coherus CEO Regarding Biosimilars User Fees
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that Coherus BioSciences’ Vice President of Government Affairs, Juliana Reed testified in support of the reauthorization of the Biosimilar User Fee Program for FY2018 –FY2022 (BsUFA II) on behalf of the Biosimilars Forum at the House Energy and Commerce Committee hearing on FDA’s generic drug and biosimilar user fee programs. Ms. Reed spoke in support of the reauthorization of B... 
Printer Friendly Version
03/02/17Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-1420 to Humira in healthy subjects.  The study met the criteria for clinical PK similarity on all prospectively defined PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first ... 
Printer Friendly Version
03/01/17Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
REDWOOD CITY, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. A company presentation is scheduled at the 37th Cowen & Co. Healthcare Conference on Monday, March 6th at 4:40 p.m. ET taking place in Boston, MA. A company presentation is scheduled at the Barclays Global Healthcare Conference on Wednesday, March 15th at 9:30 a.m. ET taking place in ... 
Printer Friendly Version
02/21/17Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
REDWOOD CITY, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, March 13, 2017.  At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing fourth quarter and full year 2016 financial results, we will post them on the Coherus BioSci... 
Printer Friendly Version
02/17/17Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective February 16, 2016, the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 155,000 shares of the company’s common stock with a per share exercise price of $23.00, the closing trading price on the grant date.  In addition, options to purchase 45,000 shares of common stock were granted to a Vice Presiden... 
Printer Friendly Version
02/08/17Coherus Prices Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced the pricing of its underwritten public offering of 5,154,640 shares of its common stock at a price to the public of $24.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 773,196 shares of its common stock at the public offering pri... 
Printer Friendly Version
02/07/17Coherus Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock at the public offering price, less the underwriting... 
Printer Friendly Version
01/31/17Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619
REDWOOD CITY, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has filed four petitions for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation of AbbVie’s U.S. Patent 9,085,619 (“ ‘619 patent”).  The ‘619 patent is generally directed to formulations of adalimumab that do not contain a buffer. “The ability of proteins to self-buffer has been known for decades.  We believe these IPRs prese... 
Printer Friendly Version
01/10/17Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
REDWOOD CITY, Calif., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (HUMIRA) biosimilar candidate. As previously reported, this study met its primary endpoint demonstrating similarity between CHS-1420 and HUMIRA with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at week 12.  The 95% confidence intervals for th... 
Printer Friendly Version
01/04/17Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 35th annual J.P. Morgan healthcare conference on Tuesday, January 10, 2017 at 2:00 p.m. PT being held in San Francisco. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a pure-play biosimilar platf... 
Printer Friendly Version